Wrapmanager Inc. increased its holdings in shares of Allergan plc (NYSE:AGN) by 1.4% in the second quarter, Holdings Channel.com reports. The firm owned 9,980 shares of the company’s stock after purchasing an additional 135 shares during the quarter. Wrapmanager Inc.’s holdings in Allergan were worth $1,671,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Clearbridge Investments LLC boosted its position in Allergan by 8.6% during the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock worth $1,342,141,000 after acquiring an additional 726,688 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Allergan by 6.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock valued at $990,867,000 after buying an additional 410,746 shares during the last quarter. FMR LLC boosted its holdings in shares of Allergan by 42.0% in the 1st quarter. FMR LLC now owns 6,042,005 shares of the company’s stock valued at $884,611,000 after buying an additional 1,788,265 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Allergan by 27.6% in the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after buying an additional 1,265,742 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Allergan by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 4,000,839 shares of the company’s stock valued at $533,767,000 after buying an additional 247,743 shares during the last quarter. 77.81% of the stock is owned by institutional investors and hedge funds.

AGN traded up $1.50 during trading hours on Tuesday, reaching $160.15. The company’s stock had a trading volume of 1,791,425 shares, compared to its average volume of 4,938,099. Allergan plc has a 52 week low of $114.27 and a 52 week high of $197.00. The company’s 50-day simple moving average is $163.05. The company has a current ratio of 1.69, a quick ratio of 1.49 and a debt-to-equity ratio of 0.39. The firm has a market cap of $52.43 billion, a price-to-earnings ratio of 9.60, a PEG ratio of 1.65 and a beta of 1.63.

Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The business had revenue of $4.09 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter in the prior year, the business earned $4.42 EPS. The firm’s revenue for the quarter was down .8% on a year-over-year basis. Analysts predict that Allergan plc will post 16.64 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th will be given a dividend of $0.74 per share. This represents a $2.96 annualized dividend and a yield of 1.85%. The ex-dividend date of this dividend is Monday, August 12th. Allergan’s payout ratio is 17.74%.

Several equities research analysts have recently commented on the company. Goldman Sachs Group assumed coverage on Allergan in a report on Tuesday, May 28th. They issued a “neutral” rating and a $154.00 price objective for the company. ValuEngine downgraded Allergan from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. UBS Group cut their price objective on Allergan from $173.00 to $172.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Svb Leerink reissued a “market perform” rating and issued a $188.00 price objective (down previously from $217.00) on shares of Allergan in a report on Thursday, July 18th. Finally, Barclays increased their price objective on Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company’s stock. Allergan presently has an average rating of “Hold” and an average price target of $180.00.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Recommended Story: FAANG Stocks

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.